Amy Morin
Psychiatric/Mental Health · Cedar Rapids, IANPI 1629617469
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by AbbVie at 58.3% of the total. Reporting peaked in 2022 at $8,102 and has fallen 53.0% since, to $3,809 in 2025. Among psychiatric/mental health clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 865 payments — averaging $27.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$14K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$863
- plus $4K from 23 others
What the payments were for
- Speaking & faculty fees$12,37552%
- Food & beverage$11,47748%
- Education$540%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 178 | $13,925 |
| Alkermes, Inc. | 80 | $1,274 |
| Neurocrine Biosciences, Inc. | 155 | $1,261 |
| Otsuka America Pharmaceutical, Inc. | 77 | $1,226 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 65 | $1,015 |
| Teva Pharmaceuticals USA, Inc. | 49 | $863 |
| Supernus Pharmaceuticals, Inc. | 28 | $700 |
| Johnson & Johnson | 43 | $537 |
| Lundbeck LLC | 32 | $510 |
| Sunovion Pharmaceuticals Inc. | 23 | $388 |
| Corium, LLC | 21 | $322 |
| Ironshore Pharmaceuticals Inc. | 18 | $311 |
| Vanda Pharmaceuticals Inc. | 15 | $252 |
| E.r. Squibb & Sons, L.L.C. | 15 | $233 |
| Almatica Pharma LLC | 14 | $224 |
| Indivior Inc. | 11 | $193 |
| Axsome Therapeutics, Inc. | 11 | $189 |
| Takeda Pharmaceuticals U.S.A., Inc. | 10 | $170 |
| Idorsia Pharmaceuticals US Inc | 5 | $69 |
| Merck | 3 | $50 |
| Harmony Biosciences LLC | 2 | $31 |
| Tris Pharma Inc | 2 | $30 |
| Bausch Health US, LLC | 2 | $28 |
| Alfasigma USA, Inc. | 1 | $24 |
| Adlon Therapeutics L.p. | 1 | $18 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,906 in reported general payments places this provider in the 95th percentile of 443 psychiatric/mental health providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 45 | $62,220 |
| LatudaLurasidone Hcl | 11 | $30,709 |
| Aripiprazole | 46 | $6,423 |
| Lurasidone Hcl | 15 | $5,892 |
| Bupropion XlBupropion Hcl | 92 | $1,877 |
| Duloxetine Hcl | 92 | $1,876 |
| Vilazodone Hcl | 16 | $1,420 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 100 | $995 |
| Clonazepam | 107 | $963 |
| Olanzapine | 25 | $803 |
| Quetiapine Fumarate | 50 | $732 |
| Escitalopram Oxalate | 96 | $706 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 23 | $601 |
| Methylphenidate Hcl | 22 | $509 |
| Zolpidem Tartrate | 99 | $430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $13,925 | $62,22045 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $388 | $30,70911 claims |
| Almatica Pharma LLCSertraline Hcl | $224 | $35556 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 443 psychiatric/mental health providers in Iowa.
Other psychiatric/mental health in Cedar Rapids
- Jennifer BradleyCedar Rapids$66K
- Abbie KelleyCedar Rapids$7K
- Natasha LashCedar Rapids$6K
- Kristina GatesCedar Rapids$6K
- Daniell DarbyshireCedar Rapids$5K
- Tarrah HollidayAtlantic$421K
- Kelsie SwisherParkersburg$235K
- Kama AusbornWaterloo$64K
- Quentin ChambersDes Moines$40K
- Tenaea JeppesonFort Dodge$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.